Achillion Pharmaceuticals Inc
ACHN:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 7.77 | 0.21 2.78% | 0.00% | 823,358 | 675.6K |
Recent News Headlines for Achillion Pharmaceuticals Inc
- Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV.
- Achillion to Present at Three Upcoming Investor Conferences
Achillion to Present at Three Upcoming Investor Conferences NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences:
- Achillion Reports First Quarter 2013 Financial Results
Achillion Reports First Quarter 2013 Financial Results NEW HAVEN, Conn., May 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2013. For the first quarter of 2013, the Company reported a net loss of $11.7 million or $0.14 per share, compared with a net loss of $9.1 million or $0.13 per share for the first quarter of 2012. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2013 were $200.9 million.
- Achillion Reports First Quarter 2013 Financial -2-
slewis@troutgroup.com (MORE TO FOLLOW) Dow Jones Newswires May 07, 2013 06:00 ET (10:00 GMT)
- Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress
Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress - Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV-